Review

Muscle Synergies in Parkinson’s Disease

Ilaria Mileti 1†, Alessandro Zampogna 2†, Alessandro Santuz 3,4,5, Francesco Asci 2, Zaccaria Del Prete 1, Adamantios Arampatzis 3,4, Eduardo Palermo 1 and Antonio Suppa 2,6,*

1 Department of Mechanical and Aerospace Engineering, Sapienza University of Rome, 00184 Rome, Italy; ilaria.mileti@uniroma1.it (I.M.); zaccaria.delprete@uniroma1.it (Z.D.P.); eduardo.palermo@uniroma1.it (E.P.)
2 Department of Human Neurosciences, Sapienza University of Rome, 00185 Rome, Italy; alessandro.zampogna@uniroma1.it (A.Z.); francesco.asci@uniroma1.it (F.A.)
3 Department of Training and Movement Sciences, Humboldt-Universität zu Berlin, 10115 Berlin, Germany; alessandro.santuz@hu-berlin.de (A.S.); a.arampatzis@hu-berlin.de (A.A.)
4 Berlin School of Movement Sciences, Humboldt-Universität zu Berlin, 10115 Berlin, Germany
5 Atlantic Mobility Action Project, Brain Repair Centre, Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia B3H 4R2, Canada
6 IRCCS Neuromed, 86077 Pozzilli (IS), Italy
* Correspondence: antonio.suppa@uniroma1.it; Tel.: +39 06 4991 4544
† The authors equally contributed to this work.

Received: 6 May 2020; Accepted: 3 June 2020; Published: 5 June 2020

Abstract: Over the last two decades, experimental studies in humans and other vertebrates have increasingly used muscle synergy analysis as a computational tool to examine the physiological basis of motor control. The theoretical background of muscle synergies is based on the potential ability of the motor system to coordinate muscles groups as a single unit, thus reducing high-dimensional data to low-dimensional elements. Muscle synergy analysis may represent a new framework to examine the pathophysiological basis of specific motor symptoms in Parkinson’s disease (PD), including balance and gait disorders that are often unresponsive to treatment. The precise mechanisms contributing to these motor symptoms in PD remain largely unknown. A better understanding of the pathophysiology of balance and gait disorders in PD is necessary to develop new therapeutic strategies. This narrative review discusses muscle synergies in the evaluation of motor symptoms in PD. We first discuss the theoretical background and computational methods for muscle synergy extraction from physiological data. We then critically examine studies assessing muscle synergies in PD during different motor tasks including balance, gait and upper limb movements. Finally, we speculate about the prospects and challenges of muscle synergy analysis in order to promote future research protocols in PD.

Keywords: Parkinson’s disease; muscle synergies; motor modules; motor primitives; electromyography; balance; locomotion; gait

1. Introduction

Parkinson’s disease (PD) globally affects 6.2 million people, representing the second most common neurodegenerative disorder after Alzheimer’s disease [1]. By 2040, it is estimated that up to 17 million people worldwide will suffer from PD, thus representing a “Parkinson pandemic” [2]. PD is a neurological disorder characterized by dopaminergic neuron depletion in the midbrain structure called the substantia nigra pars compacta and associated with intracellular and extracellular inclusions of a misfolded protein, α-synuclein [3]. The hallmark motor symptoms of PD consist of bradykinesia (i.e. movement slowness and reduction), rest tremor, and rigidity (i.e. increased muscle tone with “lead-pipe” resistance to passive movement), which are often associated with postural...
instability in more advanced disease stages [4]. L-Dopa and other drugs acting on dopaminergic transmission are the most effective medical treatment for motor symptoms in PD patients [5,6]. Nevertheless, therapeutic management of the advanced disease stages is rather challenging due to complications related to the chronic intake of drugs, such as L-Dopa-induced dyskinesia [5]. Accordingly, clinical strategies to manage advanced disease stages include pharmacological treatments based on the continuous infusion of L-Dopa/carbidopa intestinal gel or apomorphine, and non-pharmacological approaches based on deep brain stimulation (DBS) of the subthalamic nucleus and the globus pallidus pars interna [5,7].

A major challenge in the clinical management of PD patients concerns the occurrence of axial motor symptoms, including balance and gait disorders [8]. Postural instability and gait disturbances, such as the paroxysmal interruption of locomotion (i.e. freezing of gait) [9], severely affect patient quality of life by reducing individual independency and increasing the risk of falls and injuries [8]. These symptoms are largely refractory to pharmacological and non-pharmacological treatment [5]. Furthermore, since axial symptoms strongly impact the natural history of PD, they are crucial to clinically stage the disease, according to the Hoehn and Yahr scale (H&Y) [10]. Despite considerable scientific efforts to clarify the mechanisms leading to these symptoms [11–13], the pathophysiology underlying postural instability and gait disorders in PD remains largely unclear [11,14]. Accordingly, new experimental approaches are required to investigate motor control in patients with PD during balance maintenance and gait to implement current therapeutic strategies for these symptoms.

Over the last 30 years, innovative computational methods have led to the alternative approach of analysing muscle synergies in order to study human motor control [15,16]. Muscle synergy is the coordinated recruitment of a set of muscles, whose activation is strictly balanced in amplitude and timing with several possible arrangements, to perform purposeful movements [16]. According to the modular organization of motor control, muscle synergies have been proposed as a physiological model adopted by the central nervous system (CNS) to flexibly perform movements by minimizing the neural processing of motor output by producing various muscle patterns [16]. Muscles synergies have been previously demonstrated in animals [16–22] and healthy humans [23,24]. Moreover, they have also been examined in patients suffering from neurological disorders, including PD [23].

This narrative review aims to examine previous findings concerning the assessment of motor symptoms in PD patients through the analysis of muscle synergies. Accordingly, we first discuss the problem of motor control and the theoretical model of muscle synergies. We then summarise computational methods currently used to estimate muscle synergies. We critically examine previous studies addressing this topic in PD. Finally, we discuss technical and clinical challenges and speculate about the prospects of muscle synergies assessment in PD patients.

2. Muscle Synergies: Theoretical Background

2.1. The Modularity of Movement and Muscle Synergies

The motor system of vertebrates presents countless degrees of freedom, intended as the number of ways the system can independently vary, due to multiple anatomical (e.g. muscles and joints), kinematic (e.g. trajectories, accelerations, and velocities) and neurophysiological (e.g. motoneurons and neuromuscular junctions) variables that determine the execution of movements [25]. Thus, different combinations of anatomical, kinematic and neurophysiological elements can be used to achieve a specific and purposeful movement, resulting in many possible ways to perform the same motor task. Accordingly, the redundancy of the motor system and the problem of motor equivalence (i.e. multiple solutions to perform the same movement) leads to the question of how the CNS manages such high-dimensional data and selects one solution from among others [25,26]. Despite the availability of several equivalent motor solutions, movement execution commonly involves stereotyped motor behaviours (e.g. locomotion) [26,27]. This suggests that the CNS may adopt predefined strategies to solve the problem of redundant degrees of freedom and simplify motor control. Accordingly, experimental observations [17–20,28,29] support the hypothesis that motor control is based on a modular structure, consisting of basic configurations of muscle activations (i.e.
synergies) whose variable combination is responsible for several muscle patterns and complex motor behaviours [30]. Hence, through the modularity of movement (i.e. a small number of shared muscle synergies for many movements), the CNS could effectively reduce high-dimensional data to low-dimensional elements by using a few combination coefficients [30].

Over the last decades, several theoretical models of modular control have been proposed (e.g. neuromotor synergies, unit burst generators, spinal force fields) [15,29–31]. However, new computational approaches and experimental evidence ultimately led to the current concept of muscle synergies [16]. Depending on the specific motor task to be performed, the CNS manages the activation levels (spatial domain) and synchrony (temporal domain) of all muscles included in each synergy [32]. Concerning the temporal domain, in “time-invariant synergies” all muscles within the synergy are synchronously activated (i.e. without muscle activation delays), while in “time-varying synergies” each muscle shows a distinct temporal profile (i.e. reciprocal delay in muscle activation) [33]. By scaling amplitudes and muscle activation delays, the linear combination of a few muscle synergies could allow the CNS to flexibly generate a large number of different muscle patterns [32]. Some muscle synergies are task-specific, while others may be shared between different motor behaviours [34]. Moreover, sensory feedback helps to modulate the recruitment of muscle synergies and adapt motor output to the external environment [22,35] (Figure 1).

Concerning locomotion in humans, a specific number of muscle synergies can explain each phase of the gait cycle [43,44]. Four or five synergies are the minimum number required to sufficiently reconstruct the measured EMG activity during human locomotion [43,44]. These synergies also contribute to reactive balance control [45]. Moreover, previous authors have identified a small set of

---

Figure 1. A representative example of the number of synergies, motor primitives and motor modules in animals and humans while walking.

Experimental studies have supported synergistic movement in several motor conditions in cats [19,20], frogs [16,17,36] and mice [22]. One of the most relevant models comes from the study of motor control during postural tasks in cats [19]. Electromyographic (EMG) analysis of cat hindlimb muscles has shown that just four synergies could account for more than 95% of automatic postural responses during multidirectional postural perturbations [19]. These findings have demonstrated that even motor behaviour as complex as dynamic balance control can be reconducted to a small number of coordinative patterns [19]. Similarly, human studies extracted six or fewer muscle synergies during multidirectional support-surface translations by recording 16 back and leg muscles [37]. Beyond postural responses, studies in animals [20,22,38,39] and humans [40–42] have examined other motor behaviours, including locomotion and arm movements, through muscle synergy analysis. Concerning locomotion in humans, a specific number of muscle synergies can explain each phase of the gait cycle [43,44]. Four or five synergies are the minimum number required to sufficiently reconstruct the measured EMG activity during human locomotion [43,44]. These synergies also contribute to reactive balance control [45]. Moreover, previous authors have identified a small set of
muscle synergies able to reconstruct a large number of arm movements during multidirectional reaching tasks [42].

Although the neural origin of muscle synergies is highly debated [34,46,47], strong evidence from animal studies supports the existence of specific neural controllers along the CNS [34]. By using different stimulation approaches (e.g. microstimulation, N-methyl-D-aspartate iontophoresis, and cutaneous stimulation), several authors have demonstrated modular movement organization in the spinal cords of frogs, rats, and cats [15,16,28,48,49]. The activation of spinal interneuronal networks leads to stereotyped motor patterns of muscles groups, thus unveiling distinct spinal motor modules, including the central pattern generators for locomotion [50]. Experiments that involved transecting the frog neuraxis at different levels above the spinal cord have also identified neural circuits expressing muscle synergies in the brainstem, mainly in the medulla [51]. These experiments have shown that the brainstem and spinal cord express most of the muscle synergies for motor behaviours in vertebrates [51]. Conversely, high-level motor structures, including the primary motor cortex (M1) and other non-primary motor areas such as the supplementary motor cortex and premotor cortex, likely contribute to the activation and coordination of low-level neural structures to properly perform complex motor tasks, by selecting a subset of muscle synergies [34,51]. Accordingly, M1 activity relates to EMG patterns during the performance of different motor tasks in monkeys and cats [38,52,53]. Moreover, an anatomic study in monkeys [54] has demonstrated that M1 includes a rostral, phylogenetically older portion connected with spinal interneurons (“old M1”), which is likely involved in synergy modulation [38,51]. Additionally, a rostral, phylogenetically more recent division of M1 (“new M1”) directly innervates spinal motoneurons and likely activates individual muscles for more agile movements in primates [51,54]. Furthermore, the study of patients suffering from CNS lesions has contributed to the understanding of the neural substrate of muscle synergies in humans. Consistent with animal findings, patients with stroke-related lesions in motor cortical areas have shown a similar minimum number of muscle synergies to explain a specific amount of data variation in EMG signals for voluntary movements of the affected and unaffected arms [55].

Also, the two sets of synergies extracted in the affected and unaffected arms included similar muscle contributions, suggesting the preservation of low-level neural structures in patients with lesions of motor cortical areas [55]. Accordingly, the abnormal coordination of muscle synergies due to disrupted descending motor commands could explain motor performance differences between the affected and unaffected arms [51,55]. Further supporting this hypothesis, lesions of the spinal motor modules and the loss of descending motor pathways may explain muscle synergy changes in patients affected by spinal cord injuries [56,57].

2.2. Methods for Muscle Synergy Extraction

As stated above, muscle synergies are usually extracted from EMG signals [16]. The concept behind traditional extraction approaches is to identify common EMG patterns recorded from multiple muscles during any motor activity. A large number of muscle activities can be decomposed or grouped into a lower number of common activation patterns and relevant weights. For instance, during human locomotion, foot plantar flexors are used for propulsion in the second half of the stance phase, when their weight (i.e. “importance”) is highest. However, they are not as important in the early swing phase when their activity, and thus their weight for that pattern, is close to zero [44,58]. Several unsupervised machine learning methods are available that aim to identify which muscles work synergistically by linear decomposition of EMG signals [59,60]. In general, these methods attempt to build a model based on the linear combination of synergies following rules similar to:

\[
m(t) = \sum_{i=1}^{r} c_i(t)w_i + \varepsilon
\]  

where \( m(t) \) is a vector containing time-dependent activations of the recorded muscles at a specific time point (or time interval [33]) \( t \), \( r \) is the number of synergies, \( w_i \) is a time-independent vector of weights (henceforth the motor modules), \( c_i(t) \) is a time-dependent set of coefficients (henceforth the motor primitives) and \( \varepsilon \) is an error [16]. Some of these techniques include principal component
analysis (PCA), independent component analysis (ICA, a special case of blind source separation), non-negative matrix factorization (NMF), extreme learning machines (ELM) and the generalized tensor decomposition techniques [16,23,30,59–82].

While they have been shown to have similar performance [59,70], factorization approaches rely on different assumptions. For instance, PCA assumes that synergies, or the so-called principal components, are orthogonal (i.e. perpendicular). This assumption produces a unique solution for every decomposition [30,82]. If synergies are orthogonal, it follows that they are uncorrelated, allowing for an accurate estimation of how much of the total variance is explained by each synergy. However, for the orthogonality assumption to be satisfied, PCA must allow for negative motor modules [30]. This is a rather counterintuitive feature since muscle activations can be either positive (i.e. when a muscle is active) or null (i.e. when a muscle is at rest), but never negative. A method that overcomes this issue is NMF. As the name implies, NMF constrains the motor modules to be nonnegative, i.e. either positive or null. This condition allows easier interpretation of the outcomes, especially in settings such as clinical environments where qualitative interpretability may be of high value. When considering the NMF method, the linear regression of the $R^2$ vs. factorisation rank [62] and the threshold on the reconstruction quality [80] are the main approaches to determine the minimum number of synergies. Conversely, PCA commonly adopts a fixed number of muscle synergies based on the Kaiser criterion [83].

Figure 2 shows typical NMF output, where non-negative motor modules are represented as bars. A high bar translates to a high contribution (or importance) of that muscle for that specific synergy, while a low bar implies the opposite. However, the advantage of being more physiologically contextualized and understandable for lay readers come at a cost. NMF is obtained with a search algorithm that starts with random values and iteratively separates the synergies via successive iterations [84]. This process produces different, though extremely similar, solutions at every run. Moreover, since the factorized elements are not orthogonal, they are not uncorrelated, notwithstanding their linear independence (i.e. no synergy can be a linear combination of others) [30,82].

![Figure 2. Muscle synergies for human walking. Exemplary motor modules and motor primitives of the four fundamental synergies for human walking extracted via nonnegative matrix factorization (NMF) on a unilateral muscle set. Motor modules are presented on a normalized y-axis base in](image-url)
arbitrary units. For motor primitives, the x-axis full scale represents the averaged gait cycle (with stance and swing normalized to the same amount of points and divided by a vertical dotted line), while the y axis represents the normalized amplitude in arbitrary units. Muscle abbreviations: ME=gluteus medius, MA=gluteus maximus, FL=tensor fasciæ latæ, RF=rectus femoris, VM=vastus medialis, VL=vastus lateralis, ST=semitendinosus, BF=biceps femoris, TA=tibialis anterior, PL=peroneus longus, GM=gastrocnemius medialis, GL=gastrocnemius lateralis, SO=soleus.

Another important consideration on factorization methods is that each of them can be applied in many ways and outcomes can vary depending on the initial data conditions. For instance, several NMF algorithms are based on different mathematical models [63] and an acceptable consistency in results can only be obtained using different criteria, such as those required to stop the iteration process once an adequate number of synergies is found [62,63]. The necessary process of filtering EMG data before factorization is another factor that can influence outcomes. Studies have shown that it is possible to find filtering configurations that reduce the variability of the obtained NMF when calculations are done several times on the same data set [62,78,80]. Moreover, the way initial random values are selected before starting NMF plays a role in the quality of the calculated synergies [64]. Additionally, the number and choice of recorded muscles and gait cycles have been shown to influence factorization [74,75]. Indeed, the number of extracted synergies can change according to the number and type of muscles recorded (e.g. upper and lower limb muscles alone or in combination) [62,74]. Choosing at least 10 superficial muscles and recording at least a few tenths of gait cycles may be the best method to obtain consistent results [74,75]. Direct comparison of studies from different research groups also suffer some difficulties because both motor modules and primitives can undergo arbitrary normalisation procedures. Another important point is that approaches such as PCA, NMF, and ICA only allow for the identification of dependencies between two factors: motor modules (spatial factor) and motor primitives (temporal factor) [67]. When more than two factors are present in the analysis (e.g. when analysing synergy dependence on locomotion speed or motor task), a sophisticated statistical analysis must be custom built due to the low consensus currently in literature [67]. To solve this issue, a generalization of matrix decomposition, i.e. tensor decomposition, has been proposed in recent years [66,67,81]. A matrix is a two-dimensional tensor, but tensors can accommodate more than two dimensions, with the third being the locomotion speed and/or locomotor task, for example. This allows for all factors to be included in the decomposition, thus basing the entire analysis on the same statistics rather than on different approaches (e.g. NMF/PCA/ICA and then analysis of variance, or ANOVA) [66,67,81].

3. Literature Search Strategies and Criteria

Two independent researchers (I.M., A.Z.) used Medline, Scopus, PubMed, Web of Science, EMBASE, and the Cochrane Library databases to perform a literature search of studies investigating muscle synergies in PD. The following keywords were used: “Parkinson’s disease” OR “parkinsonian” OR “parkinsonism” AND “electromyography” OR “EMG” OR “factorization” AND “muscle synergies” OR “muscle coordination” OR “motor control” OR “motor module” OR “muscle modes” OR “motor primitives” AND “bradykinesia” OR “rigidity” OR “tremor” OR “balance” OR “postural responses” OR “gait” OR “locomotion” OR “movements”. Hyphens and inverted commas were used to consider all possible keyword combinations. Experimental studies based on EMG recordings that were published from January 2000 to April 2020 were considered for eligibility. Also, references of each matched article were carefully examined so as not to exclude related articles that were not identified in the electronic databases. To avoid terminology confusion, we only included findings from previous studies investigating muscle synergies intended as coordinated groups of muscle activation that are strictly balanced in amplitude and timing with several possible arrangements [32], also called muscle modes by some authors [71]. We did not address the topic of synergies as a pathological pattern of muscle activation [85] or as a neural organization of elements for the maintenance of motor stability through the concept of variables “abundance” [86]. Reviews, reports, and articles in languages other than English were also excluded from the literature search.
Eligible studies were first collected based on the title and abstract. Afterwards, full texts were evaluated according to the inclusion and exclusion criteria. Extracted data included the demographic and clinical features of PD patients (e.g. sex, age, weight, height, disease duration, clinical phenotype, disease staging and severity, therapy), experimental protocols (e.g. recorded muscles, tasks, synergy extraction) and outcome measures (e.g. muscle synergies and related parameters).

4. Muscle Synergies in Parkinson’s Disease

Ten research articles investigated muscle synergies in PD patients [71,83,87–94]. According to the aim of the study, the research articles could be divided into three main groups: (i) six articles investigating muscle synergies during postural tasks with and without external perturbations (balance) [71,83,89–91,93], (ii) three articles investigating muscle synergies during walking tasks (locomotion) [87,88,93], and (iii) two articles investigating muscle synergies during upper limb movements (resting tremor and reaching) [92,94]. Three out of the six articles investigating muscle synergies during postural tasks in PD were reported by a single research group [71,83,90]. A different team of researchers conducted two out of three studies examining muscle synergies during walking [87,88]. Lastly, two articles [89,94] re-analysed data already discussed in other manuscripts [71,83,92].

Previous studies enrolled PD patients according to different inclusion criteria, including (i) diagnosis of idiopathic PD [71,83,87–94], (ii) absence of clinically overt postural instability [71], (iii) absence of other neurological disorders [89,90] or any other comorbidity possibly affecting motor control, including polyneuropathies or significant visual, vestibular, or musculoskeletal disorders [91], (iv) absence of cognitive impairment [91,92], and (v) ability to independently perform the experimental motor tasks in any state of therapy, including active and inactive deep brain stimulation (respectively DBS-ON and DBS-OFF) [90]. Demographic and anthropometric data considered in most of the studies included: (i) age, (ii) body mass, (iii) height, (iv) sex, (v) disease onset side, and (vi) disease duration. One study also reported the number of years under therapy with DBS [90]. Each study investigating muscle synergies in PD enrolled a mean of 10 patients.

Most studies used the Unified Parkinson’s Disease Rating Scale (UPDRS) part III [71,83,88–93] and the H&Y [83,91–93] to assess motor symptoms in PD patients. Two studies provided information about patients’ clinical phenotype (i.e. tremor dominant or postural instability/gait difficulty dominant) [92,93]. Only half of the studies [83,91–93] specified the disease stage by including patients with early (i.e. H&Y I-II) and mid (i.e. H&Y III) disease stages. Only one study [91] also used the Berg balance scale to examine postural control in PD patients. Some authors evaluated cognitive function through the Mini-Mental State Examination [91,92]. Four studies reported the L-Dopa equivalent daily dose to calculate the total amount of drug intake [71,83,90,92].

The experimental tasks used to assess muscle synergy in healthy subjects (HS) and PD patients included several setups based on the motor behaviour to be studied. Balance evaluation employed various motor tasks such as quiet standing [71,83,90], self-triggered postural perturbations [71,83,90], and multidirectional external perturbations [91]. Furthermore, locomotion was analysed by measuring muscle synergies during overground walking [88,93] and walking on a treadmill [87,88]. Only one study [92] investigated muscle synergies in upper limb movements of PD patients during resting tremor and reaching tasks.

All studies investigated muscle synergies in PD patients under dopaminergic therapy (ON therapy), whereas only three studies [83,88,91] examined patients who were not under dopaminergic therapy (OFF therapy). ON therapy referred to 1-3 hours after the last drug intake [83,88,91,92] or a self-determined best medical condition [93], whereas OFF therapy required at least 12 hours of drug withdrawal [83,88,91].

All studies recorded EMG signals from a set of 22 muscles of the upper limb, upper body, or lower limb by using surface electrodes. Figure 3 summarises the recorded muscles according to the motor tasks. Six studies extracted muscle synergies by applying the NMF approach combined with the variability accounted for (VAF) (i.e. the correlation coefficient between measured EMG signals and reconstructed EMG signals) [87,88,91–94], whereas the rest used PCA with factor extraction after
Varimax rotation [71,83,89,90]. Major metrics used in the statistical analysis were: (i) number of muscle synergies at the 95% VAF [87,88,91,93]; (ii) amplitude of the individual contribution of each muscle to the muscle-weighting vectors [87,88]; (iii) amplitude and timing of the activation profile [87,88,92]; (iv) %VAF for the individual muscle [87,88]; (v) total %VAF [88,91]; and (vi) total variance of the first four muscle modes [71,83,89,90].

4.1. Balance

Concerning balance, Falaki et al. [71] used the PCA technique to assess muscle pattern during self-triggered postural perturbations (i.e. upright voluntary sway, fast sway, and a load release task), showing that in PD patients the first four muscle synergies accounted for a lower variance in muscle activation than in HS. In a further study in PD patients, the same authors [83] also demonstrated that the first four muscle synergies accounted for a higher amount of variance in patients ON as compared to OFF therapy. Conversely, a third study from the same authors found that DBS leaves these measures unchanged in patients with PD [90]. By adopting the NMF approach, Allen et al. [93] demonstrated post-rehabilitative improvement of within- and between-synergy structures (i.e. consistency, distinctness, and generalizability) without changes in the number of synergies during multidirectional translations of the support surface in PD patients. Lastly, Mileti et al. [91] demonstrated that PD patients without clinically overt postural instability use a lower number of synergies than HS to maintain upright stance in response to external postural perturbations around the vertical axis. These measures were unresponsive to L-Dopa and correlated with cognitive and motor function, as reflected by mini-mental state examination scores and the “body bradykinesia” subitem of the UPDRS-III.

4.2. Locomotion

Concerning locomotion, Rodriguez et al. [87] measured EMG activity from eight leg muscles bilaterally during a 10-minute walking task on a treadmill, demonstrating that PD patients require fewer synergies for the reconstruction of muscle activation patterns than HS. Moreover, PD patients showed abnormal motor primitives (or activation profiles) both in amplitude and timing as compared with HS, but similar motor modules (or muscle weights). The same authors [88] also demonstrated that dopaminergic therapy does not affect the number, structure, or timing of muscle synergies while walking. Muscle synergies correlated with walking speed during ON therapy, but not with stride time or length [87,88]. Similar to balance evaluation findings, Allen at al. [93] reported a post-rehabilitative improvement in consistency, distinctness, and generalizability in muscle synergies during locomotion, whereas the number of muscle synergies remained unchanged.

4.3. Upper Limb Movements

Regarding upper limb movements, Hu et al. [92] analysed the effects of transcutaneous electrical stimulation of the radial nerve on resting tremor and reaching movements in PD patients. The authors found that this experimental intervention modulates the time profile amplitude of muscle synergies differently during resting tremor and reaching tasks, but does not influence the number of synergies.

The demographic and clinical features of the PD patients included in these studies investigating muscle synergies are summarised in Table 1. Moreover, a detailed description of the methods and findings from these studies is reported in Table 2, excluding the two manuscripts [89,94] that reanalysed data already discussed in other research articles [71,83,92].

5. Discussion

To date, several studies have examined muscle synergies in PD patients to investigate pathophysiological mechanisms underlying motor symptoms and the effect of dopaminergic therapy. To this aim, several authors have used multiple motor tasks primarily involving balance and locomotion to examine muscle synergy in PD.
When comparing PD patients and HS, despite the different experimental approaches used to assess muscle synergies (e.g., muscle sets and data processing techniques), all studies consistently found a similar number of synergies between groups during postural and walking tasks [71, 87, 91]. Also, Allen et al. [93] demonstrated a similar number of muscle synergies before and after a specific neurorehabilitation protocol in PD patients. Lastly, in addition to balance and locomotion, a further study in PD patients examining upper limb movements (tremor and reaching) also confirmed a comparable number of synergies during postural and walking tasks [71, 87, 91].

Also, Allen et al. [93] demonstrated a similar number of muscle synergies before and after a specific neurorehabilitation protocol in PD patients. Lastly, in addition to balance and locomotion, a further study in PD patients examining upper limb movements (tremor and reaching) also confirmed a comparable number of synergies during postural and walking tasks [71, 87, 91]. However, the amount of variance in muscle activation that can be explained by a fixed number of synergies differed in PD patients as compared with HS, with some inconsistency. By considering an equal number of muscle synergies, Mileti et al. [91] and Rodriguez et al. [87] both observed higher %VAF values in PD patients as compared with HS. Conversely, Falaki et al. [71] found a lower amount of variance in PD patients than in HS. However, the authors considered higher [87, 91] and lower %VAF values [71] as a measure of lower motor performance in PD patients as compared with HS, making it difficult to consistently interpret these findings. There are multiple explanations for the inconsistencies among studies, including differences in patient clinical features, methodological approaches for muscle synergy extraction, and motor tasks used. Moreover, concerning locomotion, walking speed is a further confounding factor to be considered [95]. However, due to the small number of studies investigating this issue in PD and the lack of experimental assessments with muscle synergy analysis in PD animal models, it is currently difficult to reach a definitive conclusion. Despite some inconsistency among studies, some parameters obtained from muscle synergy analysis could distinguish between PD patients and HS. More in detail, when considering a fixed number of synergies, the main differences between PD patients and HS would regard the %VAF and measures of within- and between-synergy structures primarily related to the motor primitives [87, 93]. A similar consideration applies when considering the effect of L-Dopa on muscle synergies. Mileti et al. [91] and Roemmich et al. [88] demonstrated similar muscle synergies in PD patients under OFF and ON therapy during postural and locomotion tasks, seemingly consistent with the clinical observation that axial motor symptoms are frequently unresponsive to therapy [8]. In contrast with these findings, Falaki et al. [83] reported a more consistent organization of muscle synergies associated with an increased amount of %VAF during postural tasks in the ON as compared to OFF state in PD patients. Moreover, the same authors [90] found that DBS does not influence postural performance in PD patients, a finding possibly consistent with the poor DBS-related improvement of axial motor symptoms. Findings concerning muscle synergies in PD agree with previous studies in patients affected by other CNS disorders. Indeed, patients with stroke or cerebral palsy have shown heterogeneous changes in muscle synergies based on the lesion extent and location [96–98]. For instance, cortical damage in patients with stroke did not affect the internal structure but changed the modulation, of muscle synergies [55]. Conversely, extensive hemispheric strokes or brain injury in cerebral palsy significantly impacted on the number and structure of muscle synergies [97, 98]. All these observations support the hypothesis that, in humans, high-level nervous structures coordinate and modulate muscle synergy controllers that are likely localized in the spinal cord and brainstem [34].

Overall, when considering the inconsistencies among studies, several clinical and technical issues should be noted. One of the main clinical concerns regards the sample size and heterogeneity of patient cohorts. All studies on muscle synergies in PD patients included a small number of subjects (10 patients per study on average), thus implying low statistical power. Moreover, these studies mostly showed poor clinical characterization of PD patients. Accordingly, to improve the scientific quality and resolve open clinical questions, future studies should enroll larger numbers of patients. Moreover, strict inclusion criteria should include only patients selected according to the current gold standard diagnostic criteria [4] and exclude those with neurological and other medical comorbidities that may impact motor control. Demographic and anthropometric features of enrolled subjects should always be reported. Furthermore, PD patient assessment should include evaluation of the clinical phenotype (i.e., tremor dominant or postural instability/gait difficulty subtypes), as well as the severity and staging of the disease through standardized tools such as the UPDRS and H&Y. The
use of standardized clinical scales is required to accurately select homogeneous cohorts of PD patients affected by a specific clinical phenomenon. Cognitive and psychiatric disturbances, including mood disorders, should also be evaluated through standardized clinical scales such as the Montreal Cognitive Assessment, outcome scales in PD cognition, or the hospital anxiety and depression scale. According to the specific symptoms investigated, additional standardized clinical scales, such as the Berg scale for balance, the new freezing of gait questionnaire for freezing of gait, or the Timed Up and Go test for locomotion, should be adopted. This would allow a better investigation of possible clinical-behavioural correlations that could support the overall interpretation of findings. Lastly, a further crucial point in PD patients concerns the evaluation of L-Dopa effect. Indeed, the effect of PD per se can be distinguished from the effect of dopaminergic therapy only by comparing measures in patients OFF and ON therapy. Similarly, when examining the effect of DBS, all measures should be collected in patients under DBS-OFF and DBS-ON conditions, while OFF and ON therapy.

Several studies have provided methodological recommendations to allow a more comprehensive analysis and guarantee comparability of results [59,74,75,78,80,99,100]. Recommendations reported in previous studies, such as the number and selection of muscles [74], pre-processing techniques [75], filtering processes [62], number of trials [75], or factorization algorithm selection [59,62], have only partially been applied to PD cohorts. Moreover, both reliability and repeatability of EMG factorization play an important role in the correct interpretation of muscle synergies [62,80,95]. Hence, to validate the use of muscle synergies in PD, the repeatability of the synergy structure should be examined by analysing intra-trial and intra-day changes. Analysis of intrasubject repeatability, both intra- and inter-day, has already been investigated in HS [80,101]. In more advanced PD stages, motor fluctuations (OFF/ON phenomena and L-Dopa-induced dyskinesia) invariably occur and lead to dissimilarity and poor repeatability in muscle synergy measurements. The introduction of a standardized protocol to manage parkinsonian motor fluctuations and achieve acceptable measurement repeatability would likely enhance the significance of muscle synergy analysis in PD. Moreover, a deeper analysis on a wider set of indices applied to motor modules and primitives, such as the short-term maximum Lyapunov exponent [58], Higuchi’s fractal dimension [102], the Hurst exponent [103], cosine similarity [35,104], $R^2$ [62], full width at half maximum [44], and the centre of activity [105] could be useful in determining whether there are indices capable of discriminating parkinsonian motor symptoms with higher sensitivity than current measures. Lastly, defining comprehensive guidelines that take into account protocol design, data analysis, and the selection of sensitive indices would result in a more accurate analysis of muscle synergies in PD and lead to a better understanding of the pathophysiological basis of specific motor symptoms.

6. Prospects and Conclusions

Muscle synergy analysis may identify changes in PD patients, providing meaningful information about the pathophysiology of specific motor symptoms, such as locomotion and balance disorders. However, the specific CNS structures responsible for abnormal muscle synergy in PD patients remain largely unknown. Previous experimental studies in animals have demonstrated that under physiological conditions the central generators of muscle synergies are primarily located in lower-level CNS structures, such as the spinal cord and brainstem [34,51]. These lower-level structures are coordinated by higher-level regions, including the basal ganglia and cortical motor areas such as M1, the supplementary motor area, and the premotor cortex [34,51]. To date, the lack of experimental studies with muscle synergy analysis in animal models of PD makes it difficult to reach definitive conclusions about the pathophysiological role of abnormal muscle synergy in PD.

According to the current theoretical model of functional changes in the basal ganglia circuits in PD, neurodegeneration of the substantia nigra pars compacta leads to striatal dopaminergic denervation. As a result, the output nuclei of the basal ganglia, including the substantia nigra pars reticulata and globus pallidus pars interna, increase their inhibitory projections to cortical areas and the brainstem. Accordingly, dysfunctional basal ganglia circuits lead to abnormal activation of multiple subcortical dopaminergic and non-dopaminergic structures involved in balance and
locomotion, such as the mesencephalic, cerebellar, and subthalamic locomotor regions [106]. In addition to the substantia nigra pars compacta, PD is also associated with neurodegeneration of intrinsic brainstem structures, further contributing to the abnormal control of spinal generators of muscle synergy. Besides basal ganglia, cerebellum likely contributes to supraspinal modulation of muscle synergies in PD [107], according to its function in posture and gait control [108,109]. The cerebellum would play a key physiological role in the modulation of the temporal profile of muscle activation during single-joint as well as multi-joint movements [107]. Hence, the observation that L-Dopa exerts a poor effect on muscle synergies during balance and locomotion may reflect the pathophysiological involvement of non-dopaminergic pathways. This hypothesis is consistent with the clinical observation that axial motor symptoms, such as balance and gait disorders, are commonly unresponsive to L-Dopa in PD [8]. Accordingly, future studies should clarify whether alternative nonpharmacological treatments, such as those based on sensory cues [110–112], improve balance or gait in patients with PD by enhancing the activation of muscle synergies. For instance, in the context of gait, rhythmic patterns of auditory stimuli could lead to more synchronous motor behaviour by facilitating gait initiation [112–114], restoring normal patterns in gait execution [115], reducing the variability of musculoskeletal activations [116], and recruiting more consistent motor units [116] in PD patients.

In conclusion, this narrative review was designed to assess previous studies addressing muscle synergies in PD patients during specific motor tasks (e.g. balance and locomotion). Accordingly, we have first examined the theoretical background and computational methods of muscle synergies under physiological conditions. Then, we have critically discussed previous findings on this topic in PD, showing possible inconsistencies among studies. We have also speculated about the potential impact of muscle synergy analysis in providing new insights into the pathophysiology of PD motor symptoms, such as locomotion and balance disorders. Lastly, we have provided several recommendations for better designing future studies based on larger and more homogeneous cohorts of PD patients.
Table 1. Demographic and clinical features of Parkinson’s disease patients in studies investigating muscle synergies.

|   | Sex (F/M) | Age (years) | Body Weight (kg) | Height (m) | Disease Duration (years) | Onset Side (L/R/B) | Clinical Phenotype (TD/PIGD) | H&Y | UPDRS-III | BBS | MMSE | LEDD (mg) | DBS (years) |
|---|-----------|-------------|------------------|------------|--------------------------|-------------------|-------------------------------|-----|----------|-----|-------|-----------|-------------|
| [87] | -         | 67 ± 8      | 80 ± 14          | 1.7 ± 0.1  | -                        | -                 | -                            | -   | -        | -   | -     | -         | -           |
| [88] | 2 F 7 M   | 66 ± 7      | 77 ± 9           | 1.7 ± 0.1  | 4 ± 2                    | -                 | 37 ± 7                        | 41 ± 10 | -        | -   | -     | -         | -           |
| [71] | 6 F 4 M   | 69 ± 6      | -                | 3.5 ± 1.9  | 3 L 6 R 2 B              | -                 | 14 ± 10                       | -   | -        | -   | -     | 412 ± 191 | -           |
| [83] | 4 F 6 M   | 69 ± 6      | 80 ± 15          | 1.7 ± 0.1  | 6 ± 4                    | II-III            | 18 ± 10                       | 27 ± 11 | -        | -   | -     | 578 ± 144 | -           |
| [90] | 10 M      | 61 ± 10     | -                | 11 ± 5     | 3 L 6 R 1 B              | -                 | 27 ± 12*                      | -   | -        | -   | -     | 715 ± 444 | 1.57 ± 1.2  |
| [91] | 10 M      | 61 ± 4      | -                | -          | -                        | I-II              | 21 ± 8                        | 32 ± 11 | 53 ± 5   | 29 ± 2 | -     | -         | -           |
| [92] | 2 F 8 M   | 64 ± 10     | -                | 7 ± 4      | -                        | 10 TD            | I-III                         | 19 ± 4 | -        | -   | -     | 30 ± 1    | 423 ± 213   |
| [93] | 1 F 5 M   | 64 ± 17     | 72 ± 13          | 1.8 ± 0.1  | 7 ± 5                    | 1 TD 4 PIGD 1 Undet. | I-III                         | 30 ± 5 | -        | -   | -     | -         | -           |

* refers to active Deep Brain Stimulation (DBS-ON); ** refers to inactive Deep Brain Stimulation (DBS-OFF); B: Bilateral; BBS: Berg Balance Scale; DBS: Deep Brain Stimulation; H&Y: Hoehn and Yahr scale; L: Left; LEDD: Levodopa Equivalent Daily Dose; MMSE: Mini-Mental State Examination; PIGD: Postural Instability/Gait Difficulty dominant; R: Right; TD: Tremor-Dominant.
Table 2. Experimental studies investigating muscle synergies in Parkinson’s disease.

| Ref | Subjects | State of Therapy | Recorded Muscles | Experimental Task | Synergy Extraction | Main Findings | Conclusions |
|-----|----------|-----------------|------------------|-------------------|-------------------|---------------|-------------|
| [87] | 15 PD and 14 HS | ON | Eight leg muscles bilaterally: SOL, GM, TA, VM, RF, SM, BF, GLM | 10 minutes walking on a treadmill | NMF and %VAF | 95% of PD require four or fewer muscle synergies, compared to 57% HS. Similar muscle weights but shifted muscle activation profile in PD. Association between walking speed and total %VAF in PD | Altered timing of modular activation may be responsible for abnormal motor control during gait in PD, rather than different muscle weighting vectors |
| [88] | Nine PD and OFF | ON | Eight leg muscles bilaterally: SOL, GM, TA, VM, RF, SM, BF, GLM | Overground walking and walking on a treadmill | NMF and %VAF | No differences between ON and OFF therapy for total %VAF, NoS and the muscle weighting vector. Negative correlation between total %VAF and walking speed, but no correlations with other spatiotemporal gait parameters | Dopaminergic therapy does not influence the number, structure or timing of muscle synergies |
| [71] | 11 PD and 11 HS | ON | 13 leg and trunk muscle of the right side: TA, SOL, GM, GL, BF, ST, RF, VL, VM, TFL, ESL, EST, RA | Quiet standing, voluntary sway, releasing a load and fast body motion | PCA analysis with Varimax rotation and factor extraction | Four muscle synergies identified using PCA with rotation. Muscle synergies account for a lower amount of variance in PD (71.5±1.74%) than HS (78.3±1.74%). Muscle synergies are predictors of centre of pressure changes in all subjects | Organization of muscles into muscle synergies is less consistent in PD compared with HS |
| [83] | 10 PD and OFF | ON | 13 leg and trunk muscles of the right side: TA, SOL, GM, GL, BF, ST, RF, VL, VM, TFL, ESL, EST, RA | Quiet standing, voluntary sway, releasing a load and fast body motion | PCA analysis with Varimax rotation and factor extraction | Four muscle synergies identified using PCA with rotation. Muscle synergies account for a larger amount of variance in PD during ON (74.7±2.4%) than OFF (68.6±2.2%) therapy. Muscle synergies are predictors of centre of pressure changes | In PD, dopaminergic therapy makes the organization of muscles into muscle synergies more consistent during postural tasks |
| [90] | 10 PD with DBS-OFF or DBS-ON | ON | Three leg and trunk muscles of the right side: TA, SOL, GM, GL, BF, ST, RF, VL, VM, TFL, ESL, EST, RA | Quiet standing, voluntary sway, releasing a load | PCA analysis with Varimax rotation and factor extraction | In postural tasks, four muscle synergies were identified using PCA with rotation. Muscle synergies account for similar amounts of variance in DBS-OFF (75.3±2.9%) and DBS-ON (75.1±2.9%). Muscle synergies | DBS does not influence the organization of muscles into muscle synergies |
are predictors of centre of pressure changes regardless of DBS status
| Authors     | Participants | Intervention | Experimental Design | NMF and %VAF | Notes                                                                 |
|------------|--------------|--------------|---------------------|--------------|----------------------------------------------------------------------|
| [91]       | 10 PD and 10 HS ON and OFF | six upper body muscles bilaterally: PM, DP, BB, TB, EXOB, ESL | Standing while balancing external yaw perturbation | NMF and %VAF | Higher values of total %VAF in PD than HS for NoS less than 4. Similar total %VAF during OFF and ON therapy. NoS positively correlate with MMSE scores and negatively with sub-item 3.14 of UPDRS-III (“body bradykinesia”) PD use a lower number of muscle synergies to maintain balance. L-dopa does not influence muscle synergies during yaw postural perturbations. |
| [93]       | 6 PD ON      | 13 lower back and right leg muscle: RA, EXOB, EST, GLM, TFL, BF, VM, GM, GL, SOL, PL | Overground walking trial and standing while balancing a ramp-and-hold external perturbation before and after a rehabilitation program (three weeks of daily adapted tango classes) | NMF and %VAF | No differences in NoS after rehabilitation training. Rehabilitation improves motor module distinctness (i.e. well-defined biomechanical output between modules), consistency (reduced variability within motor modules) and generalizability (increased sharing of motor modules across gait and balance tasks) Within- and between-module parameters (e.g. consistency, distinctness and generalizability) reflect motor performance in PD better than NoS |
| [92]       | 10 PD and 8 HS ON | Six right arm and upper body muscles: PM, DP, BB, TB, FR, ER | Resting tremor and reaching task with and without transcutaneous electrical stimulation of the radial nerve | NMF and %VAF | Three muscle synergies were found both in resting tremor and in reaching tasks. Cutaneous stimulation does not alter synergy vectors, but differently change the time profile of muscle synergies during resting tremor and reaching tasks The different effects of cutaneous electrical stimulation on vector patterns and the time profile of muscle synergies may imply different spinal pathways for these signals |

%VAF: Variability Account For; BB: biceps brachii; BF: biceps femoris; DBS-OFF: inactive deep brain stimulation; DBS-ON: active deep brain stimulation; DP: deltoideus – posterior portion; ER: extensor carpi radialis; ESL: erector spinae lumbar region; EST: erector spinae thoracic region; EXOB: external oblique; FR: flexor carpi radialis; GL: gastrocnemius lateralis; GLM: gluteus medius; GM: gastrocnemius medialis; HS: healthy subjects; MMSE: Mini-Mental State Examination; NMF: Non-Negative Matrix Factorization; NoS: Number of Synergies; OFF: not under dopaminergic therapy; ON: under dopaminergic therapy; PCA: Principal Component Analysis; PD: patients with Parkinson’s disease; PL: peroneus longus; PM: pectoralis major; RA: rectus abdominis; RF: rectus femoris; SM: semimembranosus; SOL: soleus; ST: semitendinosus; TA: tibialis anterior; TB: triceps brachii; TFL: tensor fasciae latae; UPDRS-III: Unified Parkinson’s Disease Rating Scale- part III; VL: vastus lateralis; VM: vastus medialis.
Figure 3. Muscles recorded by surface EMG to analyse muscle synergies in Parkinson's disease patients during postural, walking and reaching tasks.
Author Contributions: Conceptualization, A.Su., E.P., I.M., A.Z.; Methodology, A.Su., E.P., I.M., A.Z., F.A., A.S., A.A.; Electronic Database Search, A.Z., I.M.; Quality Assessment, A.Su., E.P., A.S., A.Z., Z.D.P.; Writing – Original Draft Preparation, I.M., A.Z., A.S., F.A.; A.A.; Writing – Review & Editing, A.Su., E.P., A.A., Z.D.P., A.S.; Supervision, A.Su., E.P., A.A., Z.D.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations
- CNS: Central Nervous System
- DBS: Deep Brain Stimulation
- ELM: Extreme Learning Machine
- EMG: Electromyography
- H&Y: Hoehn and Yahr
- HS: Healthy Subjects
- ICA: Independent Component Analysis
- M1: Primary Motor Cortex
- NMF: Non-Negative Matrix Factorization
- PCA: Principal Component Analysis
- PD: Parkinson’s Disease
- UPDRS: Unified Parkinson’s Disease Rating Scale
- VAF: Variability accounted for

References
1. GBD 2016 Parkinson’s Disease Collaborators. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* 2018, 17, 939–953, doi:10.1016/S1474-4422(18)30295-3.
2. Dorsey, E.R.; Sherer, T.; Okun, M.S.; Bloem, B.R. The Emerging Evidence of the Parkinson Pandemic. *J. Parkinson’s Dis.* 2018, 8, S3–S8, doi:10.3233/JPD-181474.
3. Kalia, L.V.; Lang, A.E. Parkinson’s disease. *Lancet* 2015, 386, 896–912, doi:10.1016/S0140-6736(14)61393-3.
4. Postuma, R.B.; Berg, D.; Stern, M.; Poewe, W.; Olanow, C.W.; Oertel, W.; Obeso, J.; Marek, K.; Litvan, I.; Lang, A.E.; et al. MDS clinical diagnostic criteria for Parkinson’s disease. *Mov. Disord.* 2015, 30, 1591–1601, doi:10.1002/mds.26424.
5. Armstrong, M.J.; Okun, M.S. Diagnosis and Treatment of Parkinson Disease: A Review. *Jama* 2020, 323, 548–560, doi:10.1001/jama.2019.22360.
6. Suppa, A.; Bologna, M.; Conte, A.; Berardelli, A.; Fabbrini, G. The effect of L-dopa in Parkinson’s disease as revealed by neurophysiological studies of motor and sensory functions. *Expert Rev. Neurother.* 2017, 17, 181–192, doi:10.1080/14737175.2016.1219251.
7. Okun, M.S. Deep-Brain Stimulation for Parkinson’s Disease. *New Engl. J. Med.* 2012, 367, 1529–1538, doi:10.1056/NEJMct1208070.
8. Debû, B.; Godeiro C.D.O.; Lino, J.C.; Moro, E. Managing Gait, Balance, and Posture in Parkinson’s Disease. *Curr. Neurol. Neurosci. Rep.* 2018, 18, 123, doi:10.1007/s11910-018-0828-4.
9. Suppa, A.; Kita, A.; Leodori, G.; Zampogna, A.; Nicolini, E.; Lorenzi, P.; Rao, R.; Irrera, F. L-DOPA and Freezing of Gait in Parkinson’s Disease: Objective Assessment through a Wearable Wireless System. *Front. Neurol.* 2017, 8, 406, doi:10.3389/fneur.2017.00406.
10. Hoehn, M.M.; Yahr, M.D. Parkinsonism: Onset, progression and mortality. *Neuroual*. 1967, 17, 427–442.
11. Crouse, J.J.; Phillips, J.R.; Jahanshahi, M.; Mustafa, A.A. Postural instability and falls in Parkinson’s disease. *Rev. Neurosci.* 2016, 27, 549–555, doi:10.1515/revneuro-2016-0002.
12. Mazzetta, I.; Zampogna, A.; Suppa, A.; Gumiero, A.; Pessione, M.; Irrera, F. Wearable Sensors System for an Improved Analysis of Freezing of Gait in Parkinson’s Disease Using Electromyography and Inertial Signals. *Sensors* 2019, 19, doi:10.3390/s19040948.
13. Nutt, J.G.; Bloem, B.R.; Giladi, N.; Hallett, M.; Horak, F.B.; Nieuwboer, A. Freezing of gait: Moving forward on a mysterious clinical phenomenon. *Lancet Neurol.* 2011, 10, 734–744, doi:10.1016/S1474-4422(11)70143-0.
Taborri, J.; Agostini, V.; Artemiadis, P.K.; Ghislieri, M.; Jacobs, D.A.; Roh, J.; Rossi, S. Feasibility of muscle synergy combinations. *IEEE Trans. Neural Syst. Rehabil. Eng.* 2001, 9, 12–23, doi:10.1109/7333.918272.

Ting, L.H.; Macpherson, J.M. A Limited Set of Muscle Synergies for Force Control During a Postural Task. *J. Neurophysiol.* 2005, 93, 609–613, doi:10.1152/jn.00681.2004.

Krouchev, N.; Kalaska, J.F.; Drew, T. Sequential activation of muscle synergies during locomotion in the intact cat as revealed by cluster analysis and direct decomposition. *J. Neurophysiol.* 2006, 96, 1991–2010, doi:10.1152/jn.00241.2006.

D’Avella, A.; Bizzi, E. Shared and specific muscle synergies in natural motor behaviors. *Proc. Natl. Acad. Sci. USA* 2005, 102, 3076–3081, doi:10.1073/pnas.0500199102.

Santuz, A.; Akay, T.; Mayer, W.P.; Wells, T.L.; Schroll, A.; Arampatzis, A. Modular organization of murine locomotor pattern in the presence and absence of sensory feedback from muscle spindles. *J. Physiol.* 2019, 597, 3147–3165, doi:10.1113/JP277515.

Taborri, J.; Agostini, V.; Artemiadis, P.K.; Ghislieri, M.; Jacobs, D.A.; Roh, J.; Rossi, S. Feasibility of muscle synergy outcomes in clinics, robotics, and sports: A systematic review. *Appl. Biomim. Biomech.* 2018, 2018, doi:10.1155/2018/3934698.

D’Avella, A.; Portone, A.; Fernandez, L.; Lacquaniti, F. Control of fast-reaching movements by muscle synergy combinations. *J. Neurosci.* 2006, 26, 7791–7810, doi:10.1523/JNEUROSCI.1030-06.2006.

Bernstein, N.A. The coordination and regulation of movements; Pergamon Press: Oxford, UK, 1967.

Greger, R.; Windhorst, U. Comprehensive Human Physiology: From Cellular Mechanisms to Integration; Springer-Verlag: Berlin, Germany, 1996; ISBN 978-3-642-64619-5.

Lacquaniti, F. Central representations of human limb movement as revealed by studies of drawing and handwriting. *Trends Neurosci.* 1989, 12, 287–291, doi:10.1016/0166-2236(89)90008-8.

Tresch, M.C.; Bizzi, E. Responses to spinal microstimulation in the chronically spinalized rat and their relationship to spinal systems activated by low threshold cutaneous stimulation. *Exp. Brain Res.* 1999, 129, 401–416, doi:10.1007/s002210050908.

Bizzi, E.; Cheung, V.C.K.; D’Avella, A.; Saltiel, P.; Tresch, M. Combining modules for movement. *Brain Res. Rev.* 2008, 57, 125–133, doi:10.1016/j.brainresrev.2007.08.004.

D’Avella, A. Modularity for Motor Control and Motor Learning. In *Advances in Experimental Medicine and Biology*; Springer US: Boston, MA, USA, 2016; Vol. 629, pp. 3–19; ISBN 978-0-387-77063-5.

Lee, W.A. Neuromotor synergies as a basis for coordinated intentional action. *J. Mot. Behav.* 1984, 16, 135–170, doi:10.1080/00222895.1984.10735316.

D’Avella, A. Muscle Synergies. In *Encyclopedia of Neuroscience*; Binder, M.D., Hirokawa, N., Windhorst, U., Eds.; Springer: Berlin, Germany, 2009, pp. 2509–2512; ISBN 978-3-540-29678-2.

D’Avella, A.; Tresch, M.C. Modularity in the motor system: Decomposition of muscle patterns as combinations of time-varying synergies. In *Advances in neural information processing systems*; Curran Associates: Red Hook, NY, USA, 2002.

Bizzi, E.; Cheung, V.C.K. The neural origin of muscle synergies. *Front. Comput. Neurosci.* 2013, 7, 1–6, doi:10.3389/fncom.2013.00051.

Cheung, V.C.K.; Avella, A.; Tresch, M.C.; Bizzi, E. Central and Sensory Contributions to the Activation and Organization of Muscle Synergies during Natural Motor Behaviors. *J. Neurosci.* 2005, 25, 6419–6434, doi:10.1523/JNEUROSCI.4904-04.2005.

Hart, C.B.; Giszter, S.F. Modular premotor drives and unit bursts as primitives for frog motor behaviors. *J. Neurosci.* 2004, 24, 5269–5282, doi:10.1523/JNEUROSCI.5626-03.2004.
37. Torres-oviedo, G.; Ting, L.H. Muscle Synergies Characterizing Human Postural Responses. *J. Neurophysiol.* 2007, 98, 2144–2156, doi:10.1152/jn.01360.2006.

38. Yakovenko, S.; Krouchev, N.; Drew, T. Sequential activation of motor cortical neurons contributes to intralimb coordination during reaching in the cat by modulating muscle synergies. *J. Neurophysiol.* 2011, 105, 388–409, doi:10.1152/jn.00469.2010.

39. Overduin, S.A.; D’Avella, A.; Rob, J.; Bizzi, E. Modulation of muscle synergy recruitment in primate grasping. *J. Neurosci.* 2008, 28, 880–892, doi:10.1523/JNEUROSCI.2869-07.2008.

40. Monaco, V.; Ghionzoli, A.; Micera, S. Age-related modifications of muscle synergies and spinal cord activity during locomotion. *J. Neurophysiol.* 2010, 104, 2092–2102, doi:10.1152/jn.00525.2009.

41. Ivanenko, Y.P.; Poppele, R.E.; Lacquaniti, F. Five basic muscle activation patterns account for muscle activity during human locomotion. *J. Physiol.* 2004, 556, 267–282, doi:10.1113/jphysiol.2003.057174.

42. Musela, S.; Boye, A.T.; D’Avella, A.; Farina, D. Identifying representative synergy matrices for describing muscular activation patterns during multidirectional reaching in the horizontal plane. *J. Neurophysiol.* 2010, 103, 1532–1542, doi:10.1152/jn.00559.2009.

43. Santuz, A.; Ekizos, A.; Eckardt, N.; Kibele, A.; Arampatzis, A. Challenging human locomotion: Stability and modular organisation in unsteady conditions. *Sci. Rep.* 2018, 8, 1–13, doi:10.1038/s41598-018-21018-4.

44. Cappellini, G.; Ivanenko, Y.P.; Poppele, R.E.; Lacquaniti, F. Motor patterns in human walking and running. *J. Neurophysiol.* 2006, 95, 3426–37, doi:10.1152/jn.00081.2006.

45. Chvatal, S.A.; Ting, L.H. Common muscle synergies for balance and walking. *Front. Comput. Neurosci.* 2013, 7, 48, doi:10.3389/fncom.2013.00048.

46. Alessandro, C.; Delis, I.; Nori, F.; Panzeri, S.; Berret, B. Muscle synergies in neuroscience and robotics: From input-space to task-space perspectives. *Front. Comput. Neurosci.* 2013, 7, 43, doi:10.3389/fncom.2013.00043.

47. Kutch, J.J.; Valero-Cuevas, F.J. Challenges and new approaches to proving the existence of muscle synergies of neural origin. *PLoS Comput. Biol.* 2012, 8, e1002434, doi:10.1371/journal.pcbi.1002434.

48. Saltiel, P.; Wyler-Duda, K.; D’Avella, A.; Tresch, M.C.; Bizzi, E. Muscle synergies encoded within the spinal cord: evidence from focal intraspinal NMDA iontophoresis in the frog. *J. Neurophysiol.* 2001, 85, 605–619, doi:10.1152/jn.2001.85.2.605.

49. Lemay, M.A.; Grill, W.M. Modularity of motor output evoked by intraspinal microstimulation in cats. *J. Neurophysiol.* 2004, 91, 502–514, doi:10.1152/jn.00235.2003.

50. Guertin, P.A. Central pattern generator for locomotion: anatomical, physiological, and pathophysiological considerations. *Front. Neurol.* 2012, 3, 183, doi:10.3389/fneur.2012.00183.

51. Roh, J.; Cheung, V.C.K.; Bizzi, E. Modules in the brain stem and spinal cord underlying motor behaviors. *J. Neurophysiol.* 2011, 106, 1363–1378, doi:10.1152/jn.00842.2010.

52. Overduin, S.A.; D’Avella, A.; Carmena, J.M.; Bizzi, E. Microstimulation activates a handful of muscle synergies. *Neuron* 2012, 76, 1071–1077, doi:10.1016/j.neuron.2012.10.018.

53. Holdefer, R.N.; Miller, L.E. Primary motor cortical neurons encode functional muscle synergies. *Exp. Brain Res.* 2002, 146, 233–243, doi:10.1007/s00221-002-1166-x.

54. Rathelet, J.-A.; Strick, P.L. Subdivisions of primary motor cortex based on cortico-motoneuronal cells. *Proc. Natl. Acad. Sci. USA* 2009, 106, 918–923, doi:10.1073/pnas.0808362106.

55. Cheung, V.C.K.; Piron, L.; Agostini, M.; Silvoni, S.; Turolla, A.; Bizzi, E. Stability of muscle synergies for voluntary actions after cortical stroke in humans. *Proc. Natl. Acad. Sci. USA* 2009, 106, 19563–19568, doi:10.1073/pnas.0910114106.

56. Zarifia, J.; Steeves, J.; Pai, D.K. Changes in hand muscle synergies in subjects with spinal cord injury: Characterization and functional implications. *J. Spinal Cord Med.* 2012, 35, 310–318, doi:10.1179/2045772312Y.0000000037.

57. Cheng, R.; Sui, Y.; Sayenko, D.; Burdick, J.W. Motor Control After Human SCI Through Activation of Muscle Synergies Under Spinal Cord Stimulation. *IEEE Trans. Neural Syst. Rehabil. Eng.* 2019, 27, 1331–1340, doi:10.1109/TNSRE.2019.2914433.

58. Santuz, A.; Brüll, L.; Ekizos, A.; Schroll, A.; Eckardt, N.; Kibele, A.; Schwenk, M.; Arampatzis, A. Neuromotor Dynamics of Human Locomotion in Challenging Settings. *iScience* 2020, 23, 100796, doi:10.1016/j.isci.2019.100796.

59. Tresch, M.C.; Cheung, V.C.K.; D’Avella, A. Matrix factorization algorithms for the identification of muscle synergies: Evaluation on simulated and experimental data sets. *J. Neurophysiol.* 2006, 95, 2199–2212, doi:10.1152/jn.00222.2005.
60. Ting, L.H.; Chiel, H.J.; Trumbower, R.D.; Allen, J.L.; McKay, J.L.; Hackney, M.E.; Kesar, T.M. Neuromechanical Principles Underlying Movement Modularity and Their Implications for Rehabilitation. *Neuron* 2015, 86, 38–54, doi:10.1016/j.neuron.2015.02.042.

61. Bruton, M.; O’Dwyer, N. Synergies in coordination: A comprehensive overview of neural, computational, and behavioral approaches. *J. Neurophysiol.* 2018, 120, 2761–2774, doi:10.1152/jn.00052.2018.

62. Santuz, A.; Ekiros, A.; Jansen, L.; Baltzopoulos, V.; Arampatzis, A. On the Methodological Implications of Extracting Muscle Synergies from Human Locomotion. *Int. J. Neural Syst.* 2017, 27, 1750007, doi:10.1142/S0129065717500071.

63. Devarajan, K.; Cheung, V.C.K. On nonnegative matrix factorization algorithms for signal-dependent noise with application to electromyography data. *Neural Comput.* 2014, 26, 1128–1168, doi:10.1162/NECO_a_00576.

64. Soomro, M.H.; Conforto, S.; Giunta, G.; Ranaldi, S.; De Marchis, C. Comparison of Initialization Techniques for the Accurate Extraction of Muscle Synergies from Myoelectric Signals via Nonnegative Matrix Factorization. *Appl. Bionics Biomech.* 2018, 1–10, doi:10.1155/2018/3629347.

65. Shourijeh, M.S.; Flaxman, T.E.; Benoit, D.I. An approach for improving repeatability and reliability of non-negative matrix factorization for muscle synergy analysis. *J. Electromyogr. Kinesiol.* 2016, 26, 36–43, doi:10.1016/j.jelekin.2015.12.001.

66. Kolda, T.G.; Bader, B.W. Tensor decompositions and applications. *SIAM Rev.* 2009, 51, 455–500, doi:10.1137/07070111X.

67. Takiyama, K.; Yokoyama, H.; Kaneko, N.; Nakazawa, K. Speed-dependent and mode-dependent modulations of spatiotemporal modules in human locomotion extracted via tensor decomposition. *Sci. Rep.* 2020, 10, 1–15, doi:10.1038/s41598-020-57513-w.

68. Antuvan, C.W.; Bisio, F.; Marini, F.; Yen, S.C.; Cambia, E.; Masia, L. Role of Muscle Synergies in Real-Time Classification of Upper Limb Motions using Extreme Learning Machines. *J. Neuroeng. Rehabil.* 2016, 13, 76, doi:10.1186/s12984-016-0183-0.

69. Singh, R.E.; Iqbal, K.; White, G.; Hutchinson, T.E. A systematic review on muscle synergies: From building blocks of motor behavior to a neurorehabilitation tool. *Appl. Bionics Biomech.* 2018, 2018, 3615368, doi:10.1155/2018/3615368.

70. Ebied, A.; Kinney-Lang, E.; Spyrou, L.; Escudero, J. Evaluation of matrix factorisation approaches for muscle synergy extraction. *Med Eng. Phys.* 2018, 57, 51–60, doi:10.1016/j.medengphy.2018.04.003.

71. Falaki, A.; Huang, X.; Lewis, M.M.; Latash, M.L. Impaired synergic control of posture in Parkinson’s patients without postural instability. *Gait Posture* 2016, 44, 209–215, doi:10.1016/j.gaitpost.2015.12.035.

72. Kieliba, P.; Tropea, P.; Pirondini, E.; Coscia, M.; Micera, S.; Artoni, F. How are Muscle Synergies Affected by Electromyography Pre-Processing? *IEEE Trans. Neural Syst. Rehabil. Eng.* 2018, 26, 882–893, doi:10.1109/TNSRE.2018.2810859.

73. Ramos, F.M.; D’Avella, A.; Hayashibe, M. Identification of time-varying and time-scalable synergies from continuous electromyographic patterns. *IEEE Robot. Autom. Lett.* 2019, 4, 3053–3058, doi:10.1109/LRA.2019.2924854.

74. Steele, K.M.; Tresch, M.C.; Perreault, E.J. The number and choice of muscles impact the results of muscle synergy analyses. *Front. Comput. Neurosci.* 2013, 7, 105, doi:10.3389/fncom.2013.00105.

75. Oliveira, A.S.C.; Gizzi, L.; Farina, D.; Kersting, U.G. Motor modules of human locomotion: influence of EMG averaging, concatenation, and number of step cycles. *Front. Hum. Neurosci.* 2014, 8, 335, doi:10.3389/fnhum.2014.00335.

76. Endres, D.M.; Chiavetto, E.; Giese, M.A. Model selection for the extraction of movement primitives. *Front. Comput. Neurosci.* 2013, 7, 185, doi:10.3389/fncom.2013.00185.

77. Cheung, V.C.K.; Devarajan, K.; Severini, G.; Turolla, A.; Bonato, P. Decomposing time series data by a non-negative matrix factorization algorithm with temporally constrained coefficients. In Proceedings of the 2015 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Milan, Italy, 25–29 August 2015; pp. 3496–3499.

78. Shuman, B.R.; Schwartz, M.H.; Steele, K.M. Electromyography Data Processing Impacts Muscle Synergies during Gait for Unimpaired Children and Children with Cerebral Palsy. *Front. Comput. Neurosci.* 2017, 11, 1–9, doi:10.3389/fncom.2017.00050.

79. Kim, Y.; Bulea, T.C.; Damiano, D.L. Novel Methods to Enhance Precision and Reliability in Muscle Synergy Identification during Walking. *Front. Hum. Neurosci.* 2016, 10, 455, doi:10.3389/fnhum.2016.00455.
80. Taborri, J.; Palermo, E.; Del Prete, Z.; Rossi, S. On the Reliability and Repeatability of Surface Electromyography Factorization by Muscle Synergies in Daily Life Activities. *Appl. Bionics Biomech.* 2018, 1–15, doi:10.1155/2018/8582307.

81. Williams, A.H.; Kim, T.H.; Wang, F.; Vyas, S.; Ryu, S.I.; Shenoy, K.V.; Schnitzer, M.; Kolda, T.G.; Ganguli, S. Unsupervised Discovery of Demixed, Low-Dimensional Neural Dynamics across Multiple Timescales through Tensor Component Analysis. *Neuron* 2018, 98, 1099–1115, doi:10.1016/j.neuron.2018.05.015.

82. Ting, L.H.; Chvatal, S.A. Decomposing Muscle Activity in Motor Tasks - Methods and Interpretation. In *Motor Control: Theories, Experiments, and Applications*; Danion, F., Latash, M.L., Eds.; Oxford University Press: New York, NY, USA, 2011; pp. 102–138.

83. Falaki, A.; Huang, X.; Lewis, M.M.; Latash, M.L. Dopaminergic modulation of multi-muscle synergies in postural tasks performed by patients with Parkinson’s disease. *J. Electromyogr. Kinesiol.* 2017, 33, 20–26, doi:10.1016/j.jelekin.2017.01.002.

84. Lee, D.D.; Seung, H.S. Learning the parts of objects by non-negative matrix factorization. *Nature* 1999, 401, 788–791, doi:10.1038/44565.

85. Dewald, J.P.; Pope, P.S.; Given, J.D.; Buchanan, T.S.; Rymer, W.Z. Abnormal muscle coactivation patterns during isometric torque generation at the elbow and shoulder in hemiparetic subjects. *Brain* 1995, 118, 495–510, doi:10.1093/brain/118.2.495.

86. Latash, M.L. Towards physics of neural processes and behavior. *Neurosci. Biobehav. Rev.* 2016, 69, 136–146, doi:10.1016/j.neubiorev.2016.08.005.

87. Rodriguez, K.L.; Roemmich, R.T.; Cam, B.; Fregly, B.J.; Hass, C.J. Persons with Parkinson’s disease exhibit decreased neuromuscular complexity during gait. *Clin. Neurophysiol.* 2013, 124, 1390–1397, doi:10.1016/j.clinph.2013.02.006.

88. Roemmich, R.T.; Fregly, B.J.; Hass, C.J. Neuromuscular complexity during gait is not responsive to medication in persons with Parkinson’s disease. *Ann. Biomed. Eng.* 2014, 42, 1901–1912, doi:10.1007/s10439-014-1036-2.

89. Falaki, A.; Huang, X.; Lewis, M.M.; Latash, M.L. Motor equivalence and structure of variance: Multi-muscle postural synergies in Parkinson’s disease. *Exp. Brain Res.* 2017, 235, 2243–2258, doi:10.1007/s00221-017-4971-y.

90. Falaki, A.; Jo, H.J.; Lewis, M.M.; O’Connell, B.; De Jesus, S.; McInerney, J.; Huang, X.; Latash, M.L. Systemic effects of deep brain stimulation on synergic control in Parkinson’s disease. *Clin. Neurophysiol.* 2018, 129, 1320–1326, doi:10.1016/j.clinph.2018.02.126.

91. Mileti, I.; Zampogna, A.; Taborri, J.; Martelli, F.; Rossi, S.; Del Prete, Z.; Paoloni, M.; Suppa, A.; Palermo, E. Parkinson’s disease and Levodopa effects on muscle synergies in postural perturbation. In Proceedings of the Medical Measurements and Applications, Istanbul, Turkey, 26–28 June 2019; doi: 10.1109/MeMeA.2019.8802229.

92. Hu, Z.; Xu, S.; Hao, M.; Xiao, Q.; Lan, N. The impact of evoked cutaneous afferents on voluntary reaching movement in patients with Parkinson’s disease. *J. Neural Eng.* 2019, 16, 3, doi:10.1088/1741-2552/ab186f.

93. Allen, J.L.; McKay, J.L.; Sawers, A.; Hackney, M.E.; Ting, L.H. Increased neuromuscular consistency in gait and balance after partnered, dance-based rehabilitation in Parkinson’s disease. *J. Neurophysiol.* 2017, 118, 363–373, doi:10.1152/jn.00813.2016.

94. Hu, Z.X.; Xu, S.Q.; Hao, M.Z.; Xiao, Q.; Lan, N. Muscle synergy changes with cutaneous stimulation during resting tremor and reaching task in Parkinson’s disease. In Proceedings of the International IEEE/EMBS Conference on Neural Engineering, San Francisco, CA, USA, 20–23 March 2019; doi:10.1109/MeMeA.2019.8802229.

95. Shuman, B.; Goudriaan, M.; Bar-On, L.; Schwartz, M.H.; Desloovere, K.; Steele, K.M. Repeatability of muscle synergies within and between days for typically developing children and children with cerebral palsy. *Gait Posture* 2016, 45, 127–132, doi:10.1016/j.gaitpost.2016.01.011.

96. Roh, J.; Rymer, W.Z.; Beer, R.F. Evidence for altered upper extremity muscle synergies in chronic stroke survivors with mild and moderate impairment. *Front. Hum. Neurosci.* 2015, 9, 6, doi:10.3389/fnhum.2015.00006.

97. Steele, K.M.; Rozumalski, A.; Schwartz, M.H. Muscle synergies and complexity of neuromuscular control during gait in cerebral palsy. *Dev. Med. Child Neurol.* 2015, 57, 1176–1182, doi:10.1111/dmcn.12826.
98. Clark, D.J.; Ting, L.H.; Zajac, F.E.; Neptune, R.R.; Kautz, S.A. Merging of Healthy Motor Modules Predicts Reduced Locomotor Performance and Muscle Coordination Complexity Post-Stroke. *J Neurophysiol* 2010, 103, 844–857, doi:10.1152/jn.00825.2009.

99. Taborri, J.; Palermo, E.; Masiello, D.; Rossi, S. Factorization of EMG via muscle synergies in walking task: Evaluation of intra-subject and inter-subject variability. In Proceedings of the 2017 IEEE International Instrumentation and Measurement Technology Conference (I2MTC), Turin, Italy, 22–25 May 2017; pp. 1–6.

100. Scalona, E.; Taborri, J.; Prete, Z. Del; Palermo, E.; Rossi, S. EMG factorization during walking: does digital filtering influence the accuracy in the evaluation of the muscle synergy number? In Proceedings of the 2018 IEEE International Symposium on Medical Measurements and Applications (MeMeA), Rome, Italy, 11–13 June 2018; pp. 1–6.

101. Hug, F.; Turpin, N.A.; Guével, A.; Dorel, S. Is interindividual variability of EMG patterns in trained cyclists related to different muscle synergies? *J. Appl. Physiol.* 2010, 108, 1727–1736, doi:10.1152/japplphysiol.01305.2009.

102. Santuz, A.; Ekizos, A.; Kunimasa, Y.; Kijima, K.; Ishikawa, M.; Arampatzis, A. Lower complexity of motor primitives ensures robust control of high-speed human locomotion. *bioRxiv* 2020, doi:10.1101/2020.04.24.055277.

103. Santuz, A.; Akay, T. Fractal analysis of muscle activity patterns during locomotion: pitfalls and how to avoid them Running head: Fractal analysis of locomotor primitives. *bioRxiv* 2020, doi:10.1101/2020.04.24.059618.

104. Taborri, J.; Mileti, I.; Del Prete, Z.; Rossi, S.; Palermo, E. Yaw Postural Perturbation Through Robotic Platform: Aging Effects on Muscle Synergies. In Proceedings of the 2018 7th IEEE International Conference on Biomedical Robotics and Biomechatronics (Biorob), Enschede, the Netherlands, 26–29 August 2018; pp. 916–921.

105. Martino, G.; Ivanenko, Y.P.; Serrao, M.; Ranavolo, A.; d’Avella, A.; Draicchio, F.; Conte, C.; Casali, C.; Lacquaniti, F. Locomotor patterns in cerebellar ataxia. *J. Neurophysiol.* 2014, 112, 2810–2821, doi:10.1152/jn.00275.2014.

106. Israeli-Korn, S.D.; Barliya, A.; Paquette, C.; Franzén, E.; Inzelberg, R.; Horak, F.B.; Flash, T. Intersegmental coordination patterns are differently affected in Parkinson’s disease and cerebellar ataxia. *J. Neurophysiol.* 2019, 121, 672–689, doi:10.1152/jn.00788.2017.

107. Vinueza Veloz, M.F.; Zhou, K.; Bosman, L.W.J.; Potters, J.W.; Negrello, M.; Seepers, R.M.; Strydis, C.; Koekkoek, S.K.E.; De Zeeuw, C.I. Cerebellar control of gait and interlimb coordination. *Brain Struct. Funct.* 2015, 220, 3513–3536, doi:10.1007/s00429-014-0870-1.

108. Bharti, K.; Suppa, A.; Pietracupa, S.; Upadhyay, N.; Giannì, C.; Leodori, G.; Di Biasio, F.; Modugno, N.; Petsas, N.; Grillea, G.; et al. Abnormal Cerebellar Connectivity Patterns in Patients With Parkinson’s Disease and Freezing of Gait. *Cerebellum* 2019, 18, 298–308, doi:10.1007/s12311-018-0988-4.

109. Ghai, S.; Ghai, I.; Schmitz, G.; Effenberg, A.O. Effect of rhythmic auditory cueing on parkinsonian gait: A systematic review and meta-analysis. *Sci. Rep.* 2018, 8, 506, doi:10.1038/s41598-017-16232-5.

110. Thaut, M.H.; McIntosh, G.C.; Rice, R.R.; Miller, R. a; Rathbun, J.; Brault, J.M. Rhythmic auditory stimulation in gait training for Parkinson’s disease patients. *Mov. Disord.* 1996, 11, 193–200, doi:10.1002/mds.870110213.

111. Hausdorff, J.M.; Lowenthal, J.; Herman, T.; Gruendlinger, L.; Peretz, C.; Giladi, N. Rhythmic auditory stimulation modulates gait variability in Parkinson’s disease. *Eur. J. Neurosci.* 2007, 26, 2369–2375, doi:10.1111/j.1460-9568.2007.05810.x.

112. Delval, A.; Moreau, C.; Bleuse, S.; Tard, C.; Ryckewaert, G.; Devos, D.; Defebvre, L. Auditory cueing of gait initiation in Parkinson’s disease patients with freezing of gait. *Clin. Neurophysiol.* 2014, 125, 1675–1681, doi:10.1016/j.clinph.2013.12.101.

113. Hanakawa, T.; Fukuyama, H.; Katsumi, Y.; Honda, M.; Shibasaki, H. Enhanced lateral premotor activity during paradoxical gait in Parkinson’s disease. *Ann. Neurol.* 1999, 45, 329–336, doi:10.1002/1531-8249(199903)45:3<329:aaid-anu8>3.0.co;2-s.
115. Erra, C.; Mileti, I.; Germanotta, M.; Petracca, M.; Imbimbo, I.; De Biase, A.; Rossi, S.; Ricciardi, D.; Pacilli, A.; Di Sipio, E.; et al. Immediate effects of rhythmic auditory stimulation on gait kinematics in Parkinson's disease ON/OFF medication. *Clin. Neurophysiol.* **2019**, *130*, 1789–1797, doi:10.1016/j.clinph.2019.07.013.

116. Thaut, M. *Rhythm, Music, and the Brain: Scientific Foundations and Clinical Applications*; Routledge: New York, NY, USA, 2008; ISBN 9780203958827.

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).